Original Investigation

Drug-Eluting Balloon Angioplasty for Complex Femoropopliteal Lesions in Patients with End-Stage Renal Disease


  • Burak Teymen
  • Süleyman Aktürk

Received Date: 17.01.2018 Accepted Date: 16.08.2018 İstanbul Med J 2019;20(1):44-48


The aim of this study was to investigate the safety and efficacy of drug-elicited balloon (DEB) use in the interventional treatment of patients with end-stage renal disease (ESRD) and complex femoropopliteal artery lesions.


A retrospective chart review identified 30 ESRD patients who were treated for symptomatic peripheral artery disease with DEB angioplasty between September 2012 and February 2016. The inclusion criteria were having Rutherford class 2 to 6 symptoms and a critical stenosis or occlusion of the femoropopliteal artery. While restenosis or reocclusion was the primary end point, major or minor amputation was the secondary end point.


A total of 36 diabetic patients with complex femoropopliteal lesions who underwent endovascular therapy with DEB were identified. Four patients were lost during follow-up and 30 patients were included in the study. The mean lesion length was 114.6±27.8 mm. Primary patency was 73.1% and the secondary end point was 10.7% at 1-year. After a mean follow-up of 16.0±5.0 months, all-cause mortality was 7.1% (n=2). Ankle-brachial index increased from 0.42±0.04 to 0.88±0.05 postoperatively.


DEB angioplasty is efficient and safe even in long and calcified obstructive lesions including the distal superficial femoral and popliteal artery in patients with ESRD.

Keywords: Balloon angioplasty, drug-eluting balloon, endstage renal disease, peripheral interventions


Peripheral arterial disease (PAD) is more common in patients with end-stage renal disease (ESRD) undergoing hemodialysis compared to the general population. By-pass surgery is mostly not suitable since most patients with ESRD have multiple comorbidities with distal occlusions (1). Endovascular treatment (EVT) is the preferred method of revascularization in patients with femoropopliteal lesions. Percutaneous transluminal angioplasty (PTA) is mostly preferred for revascularization of femoropopliteal disease due to its relatively low risk. However, the results of balloon angioplasty alone for the complex femoropopliteal disease have been disappointing (2,3). The possibility of treating superficial femoral artery obstruction and maintaining patency rates has dramatically increased because of further device and technique development in recent years (4). Recently, drug-eluting balloon (DEB) angioplasty has been introduced to reduce femoropopliteal restenosis compared to plain old balloon (POB) angioplasty. Therefore, we analyzed our experiences with 30 femoropopliteal DEB angioplasties in ESRD patients.


Patient Population

This study was a retrospective single-center study of 34 ESRD patients (hemodialysis patients, four patients lost to follow up leaving 30 patients) with femoropopliteal arterial disease and life-style-limiting claudication who underwent DEB angioplasty between September 2012 and February 2016. The presence of Rutherford Becker class 2 or greater (Fontaine IIB) symptoms and femoropopliteal critical lesions were the inclusion criteria for our study. Mean age was 58.4±6.2 years, and 55% of patients were men. Hypertension (83.3%) and diabetes (66.7%) were the most common risk factors in this patient cohort. Baseline characteristics are summarized in Table 1.

The present study complies with the principles outlined in the Declaration of Helsinki and was approved by the Emsey Hospital Ethics Committee (no: AEK 17/009) and consent was obtained from all patients for participation in the study.


Arterial access was obtained by antegrade puncture in 24 patients and contralateral femoral puncture in 4 patients. In 2 patients, retrograde popliteal approach was preferred because of failed antegrade approach. Duplex ultrasonography (USG) and digital subtraction angiography were used for evaluation of infra-inguinal vessel calcifications. Ankle-brachial index (ABI) was measured before and after the intervention.

Intravenous heparin (100 IU/kg) was given after diagnostic angiography was performed (Figure 1A-C, 2A, 2B). Atherectomy was preferred by operator’s choice in severely calcified six lesions with suitable vessel diameter. We used a support catheter with hydrophilic guide wire for chronic total occlusions. All lesions were pre-dilated before treatment with DEB angioplasty (3 minutes inflation time, 4-7 mm 20-120 mm). The ratio of DEB to vessel diameter was planned to be 1:1. The overlap zone was more than 10 mm if multiple balloons were used per lesion. Another dilation of up to 3 minutes was performed if flow-limiting dissection or residual stenosis of more than 50% was seen. A self-expandable stent was deployed when there was flow-limiting dissection or >50% residual stenosis after DEB angioplasty. A completion angiogram concluded the procedure (Figure 2C, 3A, 3B). Patients with additional below the knee lesions were treated with DEB angioplasty (n=5). Arterial access site was managed with digital pressure. Procedural details are summarized in Table 2. Proper medication for risk factors (coronary artery disease, hypertension, and hyperlipidemia) was given with dual antiplatelet therapy (DAPT) (3 months with aspirin 100 mg + Clopidogrel 75 mg then with aspirin alone). At each follow-up visit, a duplex USG of the treated femoropopliteal site (peak systolic velocity ratio 2.5 and >50% decrease in vessel diameter was an angiography indication) and additional peripheral angiography was performed when indicated.


Technical success was defined as restoration of straight line of blood flow to the foot with a residual stenosis less than 30%. Restenosis is defined as >%50 lesion. Major amputation was defined as limb loss above the ankle, whereas minor amputation referred to below the ankle amputation or removal of more distal parts of the lower extremity.

Statistical Analysis

NCSS (Number Cruncher Statistical System) 2007 (Kaysville, Utah, USA) program was used for the statistical analysis. Data were reported as mean, standard deviation, median, frequency, and ratio. Wilcoxon signed-ranks test was used to test the difference between preop and postop values. The results were evaluated in 95% confidence interval and at a significance level of p<0.05.


Thirty ESRD patients (hemodialysis patients, four patients were lost during follow-up) who underwent EVT with DEB angioplasty for femoropopliteal lesions were enrolled. The mean follow-up time was 16.0 months. The technical success rate was 93.3%. Procedural details are summarized in Table 2. Stent implantation was needed in 2 patients because of flow limiting dissection. Two patients died due to acute myocardial infarction (10th, 11th month). These four patients were excluded from the primary and secondary end points. Seven patients with restenosis and reocclusion (73.1% patency in 26 patients, >%50 at narrowest point) were diagnosed by clinical investigation and duplex USG (Table 3). Peripheral angiography was performed in these cases after diagnosis. These patients were revascularized with EVT where bailout stent was not needed in any of them. Three amputations involving three patients were seen in this patient cohort (two minor and one major). Minor extravasation occurred when crossing a total occlusion with guide-wire in two patients. Obviously these extravasations were not seen after normal treatment protocol with balloon angioplasty. Access related hematoma occurred in three patients that resolved with manual digital pressure. The mean baseline ABI increased after the intervention, which demonstrated a hemodynamic success, and a clinical improvement with significant decrease in rutherford becker classification was seen in the patients (0.43±0.06, p<0.001) (Tables 4, 5).


ESRD is a strong determinant of atherosclerotic vascular disease and is associated with a high incidence of cardiovascular diseases. EVT of infra-inguinal lesions in ESRD patients remains a controversial issue; thus we examined the clinical and procedural outcomes of DEB angioplasty of femoropopliteal lesions in this patient cohort.

ESRD patients on dialysis with DM, frequently have calcific, long and diffuse arteriosclerotic disease in the femoropopliteal site. Therefore, these patients are often not suitable for surgery due to other comorbidities and advanced age, thus making EVT preferable. However, primary patency rate of POB angioplasty is low in multiple studies compared to DEB (3,5-8). Therefore we preferred DEB angioplasty for the treatment of femoropopliteal lesions in this study.

Nitinol or drug-eluting stents have provided better results compared to standard PTA for femoropopliteal disease, but they change the structure of the vessel and it still carries a relevant risk of restenosis, especially in long and complex lesions commonly seen in ESRD patients (5,6). Another important issue is that in-stent restenosis is more difficult to treat than restenosis in non-stented segments. Studies with DEB angioplasty have patency outcomes at least similar to stents but without leaving permanent metallic implants (9-11). Due to these facts, we preferred DEB angioplasty instead of stent deployment in our study.

EVT for PAD in ESRD patients may be technically hard because of the calcified nature of very tight stenosis or mostly occlusion, which makes the crossing by a balloon catheter and even with guide wire problematic. Through mostly antegrade femoral approach (80.0%) with using a support catheter and a hydrophilic guide wire, we crossed the lesions with a high technical success rate of 93.3% in this setting of patients.

Revascularization for peripheral arterial lesions in patients with ESRD has been controversial because of the low rates of limb preservation and short life expectancy and increased risk of dissection in this patient cohort with severe calcification (12-14). EVT, particularly with DEB angioplasty is costly. Although it seemed expensive, in a cost-effectiveness study, it appears to be better compared to local wound care alone, primary amputation or even surgical approach, especially in patients with non-healing foot wounds. (15). A recent analysis came to the conclusion that DEB angioplasty offers the lowest budget impact in the treatment of femoropopliteal lesions (16).

An alternative concept to potentially improve DEB efficacy in lesions with severe calcification (instead of pre-dilatation with a standard balloon) is to combine DEB angioplasty with directional atherectomy. After reducing plaque burden, paclitaxel can potentially inhibit cell proliferation more effectively. The DEFINITIVE AR, which is a pilot study, suggest that there is a benefit with adjuvant directional atherectomy in patients with long and calcified femoropopliteal lesions prior to using a DEB in comparison to the DEB angioplasty alone. However, the study was not sufficiently powered to detect differences in clinical outcomes. In our study, there was only one patient who needed re-intervention out of 6 patients treated with atherectomy before DEB angioplasty (16.7%). Studies with larger population are needed to evaluate the efficacy, safety, and cost-effectiveness of atherectomy as an adjuvant therapy in this patient cohort.

There is still no consensus about the duration of DAPT following DEB angioplasty (ranging from 1 to 3 months or more in different studies) (17,18). We administered a 3-month DAPT in our study. Such duration appeared safe and no acute thrombosis or major bleeding was observed during the follow-up period.

Study Limitations

This study has some limitations. First, it was a retrospective study with relatively small patient population lacking a control group. Second, we could not perform follow-up angiography in all patients and third, toe brachial index was not measured although it is needed for reliable diagnosis for PAD in this patient group (19).


DEB seems efficient and safe in the treatment of complex femoropopliteal lesions in ESRD patients. Larger and longer studies are needed to evaluate the efficacy, safety and cost-effectiveness of DEB angioplasty in this patient cohort.

Ethics Committee Approval: The present study complies with the principles outlined in the Declaration of Helsinki and was approved by the Emsey Hospital Ethics Committee.

Informed Consent: Consent was obtained from all patients for participation in the study.

Peer-review: Externally and internally peer-reviewed.

Author Contributions: Concept - B.T., S.A.; Design - B.T., S.A.; Supervision - B.T., S.A.; Resources - B.T., S.A.; Materials - B.T., S.A.; Data Collection and/or Processing - B.T., S.A.; Analysis and/or Interpretation - B.T., S.A.; Literature Search - B.T., S.A.; Writing Manuscript - B.T., S.A.; Critical Review - B.T., S.A.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

  1. Rueda CA, Nehler MR, Perry DJ, McLafferty RB, Casserly IP, Hiatt WR, et al. Patterns of artery disease in 450 patients undergoing revascularization for critical limb ischemia: implications for clinical trial design. J Vasc Surg 2008; 47: 995-9; discussion 999-1000.
  2. Dorrucci V. Treatment of superficial femoral artery occlusive disease. J Cardiovasc Surg (Torino) 2004; 45: 193-201.
  3. Jeans WD, Armstrong S, Cole SE, Horrocks M, Baird RN. Fate of patients undergoing transluminal angioplasty for lower-limb ischemia. Radiology 1990; 177: 559-64.
  4. Schneider PA. Evolution and current use of technology for superficial femoral and popliteal artery interventions for claudication. J Vasc Surg 2017; 66: 916-23.
  5. Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007; 115: 2745-9.
  6. Kasapis C, Henke PK, Chetcuti SJ, Koenig GC, Rectenwald JE, Krish- namurthy VN, et al. Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials. Eur Heart J 2009; 30: 44-55.
  7. Scheinert D, Schmidt A, Zeller T, Müller-Hülsbeck S, Sixt S, Schröder H, Weiss N, et al. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease. J Endovasc Ther 2016; 23: 409-16.
  8. Deloge C, Boesmans E, Van Damme H, Defraigne JO. Revascularization of the superficial femoral artery with paclitaxel-coated balloon for claudication. Acta Chir Belg 2018; 118: 42-7.
  9. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006; 354: 1879-88.
  10. Gray WA, Granada JF. Drug-coated balloons for the prevention of vascular restenosis. Circulation 2010; 121: 2672-80.
  11. Kayssi A, Al-Atassi T, Oreopoulos G, Roche-Nagle G, Tan KT, Rajan DK. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database Syst Rev 2016; CD011319.
  12. Ndip A, Rutter MK, Vileikyte L, Vardhan A, Asari A, Jameel M, et al. Dialysis treatment is an independent risk factor for foot ulceration in patients with diabetes and stage 4 or 5 chronic kidney disease. Diabetes Care 2010; 33: 1811-6.
  13. Kaminski M, Frescos N, Tucker S. Prevalence of risk factors for foot ulceration in patients with end- stage renal disease on haemodialysis. Intern Med J 2012; 42: e120-8.
  14. Fitzgerald PJ, Ports TA, Yock PG. Contribution of localized calcium deposits to dissection after angioplasty. An observational study using intravascular ultrasound. Circulation 1992; 86: 64-70.
  15. Barshes NR, Kougias P, Ozaki CK, Goodney PP, Belkin M. Cost-effectiveness of revascularization for limb preservation in patients with end-stage renal disease. J Vasc Surg 2014; 60: 369-374.
  16. Diehm N, Schneider H. Cost-effectiveness analysis of paclitaxel-coated balloons for endovascular therapy of femoropopliteal arterial obstructions. J Endovasc Ther 2013; 20: 819-25.
  17. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 2008; 118: 1358-65.
  18. Scheinert D. Six-month results of the Levant 1 trial. Paper presented at: Transcatheter Cardiovascular Therapeutics (TCT) Conference; 22nd Transcatheter Cardiovascular Therapeutics (TCT) Conference, September 21-25 2010, Washington, DC.
  19. Leskinen Y, Salenius JP, Lehtimäki T, Huhtala H, Saha H. The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis 2002; 40: 472-9.